Another SPAC merger with heavy hedge fund support has turned into a disaster.
On June 30, Therapeutics Acquisition Corp. (doing business as Research Alliance Corp. I), a special-purpose acquisition company sponsored by RA Capital Management, completed its merger with POINT Biopharma Inc., which is building a platform to develop radioligands that fight cancer.
